RE: Firmenich11 Jul 2022 18:55
A reminder of info rnsed by opti re DSM
April 2016 (jees 6 years now!)
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that it has entered into a joint development agreement with Royal DSM. The agreement allows for collaboration between both parties to develop new products using OptiBiotix's OptiBiotic® technology platform.
Royal DSM is a global science based company active in health, nutrition and materials with approximately 25,000 employees and annual net sales in the region of €10 billion. Its Nutritional Products business is one of the world's leading suppliers of vitamins, carotenoids, nutritional lipids and other ingredients in the food, pharmaceutical and personal care industries.
If successful, the agreement allows both parties to agree commercial terms such that OptiBiotix grants an exclusive licence to DSM in the DSM field, and an option to license in other fields, in return for royalty payments on sales of future products.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a joint development agreement with DSM, one of the world's leading suppliers of nutritional ingredients. We believe that OptiBiotix's strong science base together with DSM's innovation focus and global reach will help both companies bring better science and better health to people around the world."
https://www.optibiotix-ir.com/content/news/ir_news/05-04-16
however prior to that
Dr Gareth Barker served as a non-ex from Nov 2014 to 30 April 2019
and held 357,722 shares as at date of leaving (or at least year end 2019 report) - these relate to grant of options 10 March 2016 of 358772 (seems to be a 1000 difference ) and exercisable at 20p -
exercised
Exercise of Options, Director's Dealing and Issue of Equity
08 October 2018
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, received notification on Friday 5 October 2018 for the exercise of options over 357,722 ordinary shares in the Company at an exercise price of 20p per share providing the Company with proceeds of £71,554.
The option holder, Dr Gareth Barker, a Non-executive Director of the Company, has undertaken not to dispose of the 357,722 ordinary shares for twelve months. Dr Barker has further agreed that he will only dispose of shares through the Company's broker. After the twelve month period, the undertaking will no longer be in place.
Application will be made to the London Stock Exchange to admit the 357,722 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 11 October 2018. The new ordinary shares will rank pari passu with the existing ordinary shares.
mol
Sign In
Follow the stocks
